These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 9126693

  • 1. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials.
    Iaconis JP, Pitkin DH, Sheikh W, Nadler HL.
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S191-6. PubMed ID: 9126693
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. In vitro activity of meropenem against ciprofloxacin-resistant enterobacteriaceae and Pseudomonas aeruginosa.
    Garcia-Rodriguez JA, Blazquez AM, Fresnadillo MJ, Garcia Sanchez E, Garcia Sanchez JE, Trujillano Martin I.
    J Chemother; 1996 Oct; 8(5):358-64. PubMed ID: 8957715
    [Abstract] [Full Text] [Related]

  • 5. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis.
    Bonacorsi S, Fitoussi F, Lhopital S, Bingen E.
    Antimicrob Agents Chemother; 1999 Feb; 43(2):213-7. PubMed ID: 9925508
    [Abstract] [Full Text] [Related]

  • 6. Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers.
    Pitkin DH, Sheikh W, Nadler HL.
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S238-48. PubMed ID: 9126699
    [Abstract] [Full Text] [Related]

  • 7. Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases.
    Livermore DM, Chen HY.
    J Antimicrob Chemother; 1997 Sep; 40(3):335-43. PubMed ID: 9338484
    [Abstract] [Full Text] [Related]

  • 8. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
    Humphries RM, Hindler JA, Wong-Beringer A, Miller SA.
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. In Vitro Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for Pseudomonas aeruginosa.
    Goodlet KJ, Nicolau DP, Nailor MD.
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antimicrobial Effects of β-Lactams on Imipenem-Resistant Ceftazidime-Susceptible Pseudomonas aeruginosa.
    Wi YM, Choi JY, Lee JY, Kang CI, Chung DR, Peck KR, Song JH, Ko KS.
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373200
    [Abstract] [Full Text] [Related]

  • 13. Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multiresistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ, Grecka P, Giamarellou H.
    Diagn Microbiol Infect Dis; 1997 Oct; 29(2):81-6. PubMed ID: 9368083
    [Abstract] [Full Text] [Related]

  • 14. In-vitro activity of meropenem, a new carbapenem, against multiresistant Pseudomonas aeruginosa compared with that of other antipseudomonal antimicrobials.
    Voutsinas D, Mavroudis T, Avlamis A, Giamarellou H.
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():143-7. PubMed ID: 2509412
    [Abstract] [Full Text] [Related]

  • 15. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
    Jones RN, Kirby JT, Beach ML, Biedenbach DJ, Pfaller MA.
    Diagn Microbiol Infect Dis; 2002 Jul; 43(3):239-43. PubMed ID: 12106958
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.
    Buehrle DJ, Shields RK, Chen L, Hao B, Press EG, Alkrouk A, Potoski BA, Kreiswirth BN, Clancy CJ, Nguyen MH.
    Antimicrob Agents Chemother; 2016 May; 60(5):3227-31. PubMed ID: 26976862
    [Abstract] [Full Text] [Related]

  • 17. In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa.
    Tessier F, Quentin C.
    Eur J Clin Microbiol Infect Dis; 1997 Feb; 16(2):159-62. PubMed ID: 9105845
    [Abstract] [Full Text] [Related]

  • 18. Relationship between outer membrane protein profiles and resistance to ceftazidime, imipenem, and ciprofloxacin in Pseudomonas aeruginosa isolates from bacteremic patients.
    Gimeno C, Navarro D, Savall F, Millás E, Farga MA, Garau J, Cisterna R, García-de-Lomas J.
    Eur J Clin Microbiol Infect Dis; 1996 Jan; 15(1):82-5. PubMed ID: 8641311
    [Abstract] [Full Text] [Related]

  • 19. In-vitro activity of meropenem, a new carbapenem, against imipenem-resistant Pseudomonas aeruginosa and Xanthomonas maltophilia.
    García-Rodríguez JA, García Sánchez JE, Muñoz Bellido JL, García Sánchez E, García García MI.
    J Chemother; 1991 Jun; 3(3):143-6. PubMed ID: 1919651
    [Abstract] [Full Text] [Related]

  • 20. In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa.
    Shibata K, Adachi Y, Kato E, Nagano R, Fuse A, Hashizume T, Ohtake N, Okamoto O, Nakagawa S.
    J Antibiot (Tokyo); 1997 Feb; 50(2):135-8. PubMed ID: 9099222
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.